Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iron-containing versus calcium-containing phosphate binder treatment in CKD-MBD
2017-002095-10Phase 4Terminated
- Sponsor
- University Clinic of Nephrology and Hypertension, Regional Hospital Holstebro
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of iron sucrose in chronic kidney disease-mineral and bone disorder (CKD-MBD) and hyperphosphatemia (2 arms), sponsored by University Clinic of Nephrology and Hypertension, Regional Hospital Holstebro. Primary endpoints: SUVmax and Ki. Started Jun 2017; status: terminated.
02
Drugs
iron sucrose
03
Conditions
chronic kidney disease-mineral and bone disorder (CKD-MBD)hyperphosphatemia
Beyond the preview
Go deeper on 2017-002095-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002095-10.